In a study published in the International Journal of Pharmaceutics, ISMO researchers have published the first study of an innovative strategy that combines porous organometallic nanoparticles (nanoMOFs) loaded with the anti-cancer drug Gemcitabine monophosphate (GemMP) and helium and carbon ion hadrontherapy.